Clinical trial
A Randomized, Double-blind, Placebo-controlled, 2-part Study of Orally Administered AK0529 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Multiple Doses in Hospitalized Infants With Respiratory Syncytial Virus Infection
NCT04231968 is registered in ClinicalTrials.gov with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, 2-part Study of Orally Administered AK0529 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Multiple Doses in Hospitalized Infants With Respiratory Syncytial Virus Infection
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 22, 2020
- Completion date
- February 2, 2022
- Enrollment
- 311 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.